What A Cancer Vaccine Stumble Means For Moderna Stock
Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?
Moderna (MRNA) holders face a big question: what if its cancer vaccine with Merck falls short? In a late-stage trial, patients who added the vaccine to their treatment saw their risk of melanoma returning or death fall by 42%. Yet when those results leaked in October, the news set off heavy selling. Investors questioned the vaccine’s potential across other cancers. So if the vaccine stumbles, what is at risk: Moderna’s sales, or the price of its shares?

Moderna’s Share Price Has More To Lose Than Sales
A setback would barely affect Moderna’s sales because the cancer vaccine is not yet approved. The company still generates almost all of its revenue from COVID vaccines, which made up 94.2% of sales in fiscal 2025.
The share price tells a different story. At the November 19 close, Moderna stock traded at 31.7 times its sales over the past 12 months, compared with 3.1 times for the S&P 500. This gap suggests buyers are paying for much more than COVID vaccines. The melanoma vaccine is the program Moderna and Merck are working to submit for approval in 2026.
Moderna stock has also fallen far more than the market before. In the 2022 inflation shock, it fell 50%, against 24% for the S&P 500. In the month to November 19, it lost 18.9%, while the index lost 7.4%. Over the year to November 19, the stock gained about 700%, against 9.7% for the index.
Moderna stock lost 18.9% in one month, and it sends its holders no cash while they hold on. If you need your savings to bring in steady money, swings like that are hard to sit through. The Trefis Income Solution pays a dividend yield about 3 times the S&P 500’s, from 50 companies that have paid dividends for at least 10 years in a row. See what it pays.
How Much Cash Moderna Has If The Vaccine Stumbles
On September 30, 2026, Moderna held $5.17 billion in cash and short-term investments. It also owed $4.23 billion of debt. Over the past 12 months, the company spent $2.04 billion more cash than it took in. At that pace, its cash and short-term investments would cover about two and a half years of spending. That count uses all of the cash and sets none aside to repay the debt.
The company borrowed much of that cash. During the third quarter, Moderna raised about $2.6 billion in net proceeds from a 0% convertible note.
The COVID business is also growing again. Third-quarter revenue rose 30.9% from a year earlier. Management said higher COVID sales drove most of the increase. Moderna now forecasts 2026 revenue growth of 15% to 25%. In its July guidance, the forecast was up to 10%.
When Moderna Holders Will Hear About The Vaccine
The first sign will come when Moderna and Merck ask regulators to approve the vaccine. On the November 6 call, management said the two companies are working to file that request in 2026. Moderna hopes to see approval in 2027. Moderna also expects results from a phase 2 trial in another cancer, involving 282 patients, at the end of 2026 or early in 2027.
Moderna is expected to report in February 2027. That report will show management’s measure of cash and investments at the end of 2026, which it projects at $8.1 billion to $8.3 billion. Management put that measure at $8 billion on September 30, a different measure from the $5.17 billion figure above.
So much now waits on one approval decision. You can decide today how much of your money to keep in a single stock, and when you would sell.
Too Much Riding On One Stock?
If Moderna is a big part of your wealth, so are its risk and its tax bill. What’s your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
Spot an error or want more like this? Tell us in 10 seconds.